"Designing Growth Strategies is in our DNA"
The global neuropathic pain market size was valued at USD 7.37 billion in 2023. The market is projected to grow from USD 7.79 billion in 2024 to USD 14.05 billion by 2032, exhibiting a CAGR of 7.7% during the forecast period. North America dominated the neuropathic pain market with a market share of 49.93% in 2023.
Neuropathic or nerve pain is caused due to damage or dysfunction of the nervous system. This type of pain is mostly chronic and hinders the normal daily activity of the patients. Treatment option for neuropathic pain management includes medications, implantable medical devices, and surgery.
Neuropathy pain therapeutics, such as gabapentin and capsaicin, are quite effective in nerve pain management. Patients who have diabetes, shingles, or undergoing chemotherapy are more prone to nerve pain. Therefore, the growing burden of these conditions has been fueling the demand for effective nerve pain therapeutics.
During the COVID-19 pandemic in 2020, neuropathy pain therapeutics experienced a decline in its revenue due to the implication of lockdown, which restricted the population from visiting the doctors for the treatment of these types of pain, as the hospital visits were reduced to control the spread of the virus. However, in 2021 and 2022, the market experienced significant growth due to the increased burden of patients suffering from these type of pain and the increased number of patients visiting hospitals and clinics.
Market Players Have Been Emphasizing R&D for Novel Therapeutics Development
The increasing burden of neuropathic pain among patients who have cancer or diabetes or have gone through certain surgeries has increased the demand for effective treatment options. To fulfill this increasing demand, market players have increased their focus on novel and effective therapeutics development to manage neuropathy pain effectively.
The launch of these therapeutics will increase the availability of effective pain management options and will also fuel the market growth over the forecast period.
Request a Free sample to learn more about this report.
Growing Burden of Chronic Diseases Responsible for Neuropathic Pain has been Fueling the Demand for Effective Therapeutics
Neuropathic pain is often associated with diseases, such as cancer, diabetes, multiple sclerosis, kidney diseases, and shingles. Therefore, the growing burden of these diseases has been fueling the risk of nerve pain.
The high burden of these diseases has also been fueling the occurrence of nerve pain among these patients.
The increasing burden of diabetic neuropathy has also been fueling the demand for effective pain management options. To fulfil this, market players have increased their focus on new product launches.
Therefore, the growing demand for nerve pain management therapeutics, along with the increasing focus of the market players on new product launches, has been fueling the neuropathic pain market growth.
Side Effects associated with the Use of Neuropathic Pain Medication has been Restricting the Market Growth
The growing burden of nerve pain due to diabetes, chemotherapy, and other nervous system injuries has been fueling the demand for effective therapeutics.
However, there are certain side effects associated with the use of nerve pain therapeutics, such as dizziness, nausea, dry mouth, and edema, among others, restrict patients from adopting these therapeutics.
All the factors mentioned above restrict the patients from taking these therapeutics. Due to this, patients prefer going for alternate options, such as devices and surgeries for pain management.
Strong Availability of Anticonvulsant Drugs and Increasing Prevalence of Neuropathic Pain Fueled Segment Growth
On the basis of drug class, the global market is segmented into anticonvulsants, tricyclic antidepressants (TCA), opioids, capsaicinoids, and others.
The anticonvulsants segment dominated the market in 2023. The segment’s dominance is attributed to the increasing demand for effective pain management options for diabetic neuropathy along with the strong availability of anticonvulsant drugs, such as Gralise, Horizant, Neurontin, Lyrica, and OXTELLAR XR, in the market.
Moreover, the others segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the increasing focus of the market players on conducting clinical trials for the development of novel therapeutics.
To know how our report can help streamline your business, Speak to Analyst
Increasing Prevalence of Cancer Fueled Demand for Effective Chemotherapy Induced Neuropathy Pain Management
Based on the application, the market is segmented into diabetic neuropathy, chemotherapy induced neuropathy, sciatic neuropathy, and others.
The chemotherapy induced neuropathy segment dominated the market by accounting for the major proportion of the global neuropathic pain market share in 2023. The segment’s dominance is attributed to the growing burden of cancer, which has been increasing the number of patients undergoing chemotherapy, thereby increasing the chemotherapy induced neuropathy.
Furthermore, the diabetic neuropathy segment is expected to grow at the fastest CAGR during the forecast period. The segment’s growth is attributed to the increased focus of the pharmaceutical and biopharmaceutical industry on research and development of novel therapeutics.
Strong Presence of Neuropathy Pain Therapeutics in Oral Forms Boosted Segement’s Dominance
On the basis of the route of administration, the market is bifurcated into oral and parenteral.
The oral segment dominated the market in 2023 and is expected to grow at the fastest CAGR during the forecast period. The segment’s dominance is attributed to the availability of a variety of oral therapeutics for nerve pain management, such as Lyrica, OXTELLAR XR, and Trileptal, among others.
Furthermore, the parenteral segment is expected to grow at a substantial CAGR during the forecast period. The segment’s growth is attributed to the increasing focus of pharmaceutical and biotechnology companies on the development of effective novel therapeutics.
Retail Pharmacy Dominated the Market Due to the Easy Availability of Medications
Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Retail pharmacy dominated the global neuropathic pain therapeutics market in 2023. The segment’s dominance is attributed to the increasing demand for topical nerve pain medications, such as Elavil and AneCream5, which are easily available at retail pharmacies.
The online pharmacy segment is expected to grow at the fastest CAGR during the forecast period. The segment's growth during the forecast period is attributed to the increasing availability of prescription as well as off-label drugs on online channels. Moreover, the increasing preference of individuals to buy products conveniently without actually visiting the stores has also been fueling the segment’s growth.
Based on geography, the neuropathic pain market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America Neuropathic Pain Market Size, 2023 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
North America dominated the market in 2023, accounting for USD 3.68 billion of the global market. The high growth of the market in North America is attributed to the strong presence of market players, such as Almatica, Azurity Pharmaceuticals, Inc., Pfizer Inc., and Viatris Inc., among others in the region. Furthermore, increasing awareness regarding neuropathic pain has been fueling the demand for effective therapeutics, thereby fueling the market growth in the region.
The market in Europe is expected to grow at a substantial CAGR during the forecast period due to the growing burden of cancer and diabetes in European countries.
The Asia Pacific market is expected to grow at a significant CAGR during the forecast period. The growth of the market in the region is attributed to the increasing focus of the pharmaceutical industry on R&D activities for the development of novel therapeutics.
The markets in Latin America and the Middle East & Africa are expected to grow at a substantial CAGR in the coming years. The high growth rate in these regions is attributed to the growing burden of chronic diseases and rising awareness about the therapeutics that effectively manage nerve pain.
Increasing Focus of the Market Players on Partnerships and Acquisitions to Enhance their Product Offerings
Market players, such as Novartis AG, Pfizer Inc., and Viatris Inc., are among the major players, accounting for a significant share of the global market. The significant presence of these companies in the market is attributed to their focus on the expansion of product offerings for nerve pain management.
Moreover, other players, such as Almatica Pharma LLC, Accord Healthcare, and Abbott, among others, have been focusing on new product launches to enhance their presence in the market.
The global neuropathic pain market report provides a detailed competitive landscape and market insights. It also includes key insights, such as top industry developments covering partnerships, mergers, and acquisitions. Additionally, it focuses on key points, such as new solution launches in the market. Furthermore, the report covers regional analysis of different market segments, profiles of key market players, market trends, and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights that have contributed to the market's growth.
To gain extensive insights into the market, Request for Customization
ATTRIBUTE | DETAILS |
Study Period | 2019-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2019-2022 |
Growth Rate | CAGR of 7.7% from 2024-2032 |
Unit | Value (USD billion) |
Segmentation | By Drug Class
|
By Application
| |
By Route of Administration
| |
By Distribution Channel
| |
By Region
|
Fortune Business Insights says that the global market stood at USD 7.37 billion in 2023 and is projected to reach USD 14.05 billion by 2032.
In 2023, the market value for North America stood at USD 3.68 billion.
The market is predicted to exhibit a CAGR of 7.7% during the forecast period.
By drug class, the anticonvulsants segment led the market.
The growing burden of chronic diseases, along with the increasing focus of the market players on new product launches, has been fueling the market growth.
Novartis AG, Pfizer Inc., and Viatris Inc. are the top players operating in the market.
US +1 833 909 2966 ( Toll Free )